

ASX Announcement | Monday 8 April 2024 AdAlta Limited (ASX:1AD)

AdAlta webinar to discuss new SYNthesis BioVentures partnership and business progress

AdAlta Limited (ASX:1AD) (“AdAlta” or “the Company”), is pleased to announce Chief Executive Officer and Managing Director, Tim Oldham will host a webinar to discuss AdAlta’s new collaboration with SYNthesis BioVentures under a Memorandum of Understanding (MoU) announced on Monday 8 April 2024 and general business progress.

Date Wednesday 10 April 2024

Time 11:00 AEDT

Format Zoom

Register The event is free and investors can register online here:
https://us02web.zoom.us/webinar/register/WN_86kBPnJVTja6QmLsty2i7Q

A recorded copy of the webinar will be made available following the event on AdAlta’s InvestorHub:

<https://investorhub.adalta.com.au/>

For further information, please contact:

AdAlta Limited (ASX:1AD)
Tim Oldham
CEO & Managing Director
P: +61 3 9479 5159
E: t.oldham@adalta.com.au

Media & Investor Enquiries
The Capital Network
Russell Katz
P: +61 2 8999 3699
E: russell@thecapitalnetwork.com.au

About AdAlta Limited

AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody enabled protein and cell therapeutics with the potential to treat some of today’s most challenging medical conditions.

The i-body technology mimics the shape and stability of a unique and versatile antigen binding domain that was discovered initially in sharks and then developed as a human protein. The result is a range of unique proteins capable of interacting with high selectivity, specificity and affinity with previously difficult to access targets such as G-protein coupled receptors (GPCRs) that are implicated in many serious diseases. i-bodies are the first fully human single domain antibody scaffold and the first based on the shark motif to reach clinical trials.

AdAlta has completed Phase I clinical studies for its lead i-body candidate, AD-214, that is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases for which current therapies are sub-optimal and there is a high unmet medical need. The Company is advancing partnering discussions to finance Phase II clinical studies, preparation for which is underway.

The Company is also entering collaborative partnerships to advance the development of its i-body® platform and expand its clinical stage pipeline. It has a collaboration with Carina Biotech to codevelop precision engineered, i-body® enabled CAR-T cell therapies (i-CAR-T) to bring new hope to patients with cancer. It has an agreement with GE Healthcare to co-develop i-bodies as diagnostic imaging agents (i-PET imaging) against Granzyme B, a biomarker of response to immuno-oncology drugs, a program now in preclinical development. It has entered a Memorandum of Understanding with SYNthesis BioVentures to investigate the formation of a jointly owned entity, to be called AdCella, that, once established, will provide innovative cellular immunotherapies originating in Asia with a pathway to western regulated markets via Australian clinical trials and further enhancement with AdAlta's i-body® technology.

AdAlta's strategy is to maximise the products developed using its next generation i-body® platform by internally discovering and developing selected i-body® enabled product candidates against GPCRs implicated in fibrosis, inflammation and cancer and partnering with other biopharmaceutical companies to develop product candidates against other classes of receptor, in other indications, and in other product formats.

For more information



Follow us on [Twitter](#)



Follow us on [LinkedIn](#)

To learn more about AdAlta please visit: www.adalta.com.au